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Understanding the molecular mechanisms that precede
and give rise to a migraine attack is key to developing new
therapeutic strategies. Advances towards this goal have
recently been made through genome-wide association
studies, which have identified new genetic components of
migraine that highlight vascular etiologies and underline
the polygenic nature of this disorder.
Understanding the polygenic basis of migraine
As the most prevalent and disabling neurological disorder,
migraine affects the lives of millions of people worldwide,
and for many there are still no effective treatments.
Genome-wide association (GWA) studies are an import-
ant approach used to uncover the genetic susceptibility
components of complex diseases such as migraine. The
most recent GWA study [1], which was conducted by
groups including our own, has identified 38 genomic loci
commonly found in humans (>5 % allele frequency) that
influence migraine risk. Earlier studies [2–4] have impli-
cated additional loci, putting the total number of genomic
regions associated with migraine as high as 47. These loci
represent great progress in the field and provide cause for
optimism that key mechanisms can eventually be under-
stood. However, as is typical in GWA studies, the impact
of each individual locus on disease risk is relatively modest
(odds ratios <1.2), thus making it difficult (and perhaps
not useful) to interpret the contribution of any one impli-
cated gene to migraine pathophysiology. Instead, the
power of these genomic loci comes from assessing their
contribution as a group, whereby through aggregation in
certain pathways or other functional classifications they
can provide a map towards biological mechanisms of the
disease. In this way, new hypotheses can be generated that* Correspondence: pgormley@broadinstitute.org
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Part of the problem in understanding the biological
underpinnings of migraine has been that there are no
known or measurable biomarkers for the disease. Fur-
thermore, the common forms of migraine have been
firmly established as polygenic disorders [1–3] in which
likely hundreds of genetic variants across the genome
accumulate in varying combinations to give rise to the
spectrum of disease outcomes. Understanding how these
different combinations of variants (along with the multi-
tude of environmental triggers) can influence the level of
risk across individuals and produce specific disease out-
comes is a complex problem to solve. For instance, it is
not clear how genetic variation and triggers may inter-
act, nor is it clear what might be the contribution of rare
variation. Answers to these questions will be revealed
only with appropriately designed study populations.
An important aspect for a successful study is the sample
size, where genotyping larger numbers of cases and con-
trols facilitates, by boosting statistical power, the identifica-
tion of true risk loci. The most recently published migraine
study, comprising data from 375,000 individuals, repre-
sents the largest published GWA study of any specific dis-
ease [1]. Collecting such numbers is usually only possible
through international collaborations that span academic,
clinical, and commercial institutions. In this study [1], part-
nerships with commercial entities were hugely important
to increase the sample numbers. For example, out of
375,000 individuals, the companies 23andMe and deCODE
together provided data from 56 % (or 33,600) of the total
cases and 76 % (or 238,732) of the total controls. These
public–private partnerships should be encouraged in future
studies as they benefit all interested parties, and the pool-
ing of all available resources can only help speed up new
discoveries. Of course, it should be remembered that the
contributions from academic or clinical institutions are
equally important because these tend to consist of more
severe cases and better phenotyped collections that canle is distributed under the terms of the Creative Commons Attribution 4.0
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questions to be investigated [5].
Here we outline the major findings from the latest
GWA study of migraine [1] and discuss what they reveal
about both the pathophysiology and genetic architecture
of the disease. We further discuss the implications of these
findings for translational research and clinical treatment.
Key genomic loci implicated in migraine: a more
central role for vascular etiologies
A key finding from the most recent migraine GWA
study [1] was that the 38 identified loci were enriched
for genes that are expressed most actively in arterial tis-
sue. This is an interesting discovery because although
migraine is known to have an impact on vascular func-
tion, it was thought that this most likely represented
downstream effects from neuronal activity rather than
pathology of the vasculature itself. These findings sug-
gest that vascular dysfunction plays a much more central
role in migraine pathophysiology and could even be
more important than the neuronal component in some
individuals. This vascular discovery aligns well with
known co-morbidities and shared polygenic risk between
migraine, stroke, and cardiovascular diseases [6, 7].
Furthermore, the lead single-nucleotide polymorphism
identified in the PHACTR1 locus for migraine has also
been identified as the lead polymorphism associated with
several vascular diseases (coronary heart disease, coronary
artery calcification, and cervical artery dissection) [1]. For
cervical artery dissection, there also appears to be overlap
with migraine at two more loci (LRP1 and FHL5) [8],
suggesting the possibility of partially shared genetic com-
ponents between migraine and these diseases.
However, the likelihood that neuronal dysfunction still
has an important role in migraine pathophysiology
should not be discounted because, although the 38 loci
as a group were not found to be enriched in the brain,
several individual loci showed strong expression in spe-
cific brain tissues. Furthermore, compared with vascular
and other tissues, well-characterized brain samples are
more difficult to obtain for research purposes and, there-
fore, perhaps the specific brain tissue most relevant for
migraine has not yet been assayed. It is also possible that
when more loci are identified through future studies, an
enrichment in brain tissues will become clear.
Previous hypotheses of molecular mechanisms in mi-
graine have come from familial hemiplegic migraine
(FHM), a rare Mendelian form of the disease, where three
ion channel genes are known to be involved (CACNA1A,
ATP1A2, and SCN1A) [9]. These findings propagated the
theory that more common forms of migraine might also
be characterized as channelopathies. However, in the re-
cent study only two ion channel genes were identified out
of the entire set of 38 loci (KCNK5 and TRPM8) [1]. Thisalso agrees with earlier studies suggesting that ion channel
dysfunction is not the most important pathophysiological
mechanism in common forms of migraine [10]. However,
genes at three other migraine-associated loci (SLC24A3,
ITPK1, and GJA1) have been linked to ion homeostasis, so
it is possible that genes more generally involved in this
biological process could have a role.
The recent findings [1] are also beginning to reveal the
genetic architecture of migraine and its common sub-
types: migraine with aura (MA) and migraine without
aura (MO). For example, in a subset analysis consisting
of individuals with only MO, seven loci were identified,
whereas for individuals specifically suffering from MA,
no associated loci were found [1]. This seems to suggest
that the genetic architecture of these two forms is quite
different. However, in a follow-up heterogeneity analysis
[1], most of the 38 loci were actually implicated in both
migraine subtypes, suggesting that the absence of signifi-
cant loci for MA is mainly due to lack of statistical
power from the lower number of samples available. To
add weight to this argument, estimates of heritability
(based on linkage disequilibrium score regression) found
that the MA dataset captured less of the heritability than
the MO dataset, such that approximately twice the sam-
ple size would be required to reach equivalent power for
MA as was obtained for MO [1]. Possible explanations
for these differences are that greater heterogeneity might
have been introduced in the clinical phenotyping, that
low frequency or rare variation may contribute more to
the risk, or perhaps even that the underlying biology of
MA is simply more complex.
Conclusions and clinical implications
Although the advances in GWA studies represent major
progress, it is perhaps too early to say whether, in the
short term, the common variant loci found could dir-
ectly help to influence patient care. Certainly, the magni-
tude of the genetic effects are not sufficient to make
predictions of migraine outcomes in individuals, as the
proportion of the heritability explained by these loci is,
on aggregate, very low. In the longer term, however,
there are great opportunities to make improvements by
sub-classification of individuals based on their genetic
profile and the potential for tailoring treatments specific
to individual patients.
Before this, however, appropriate investigation would
be required of the genetic factors influencing the vari-
ability in response to certain treatments. For example,
we still do not understand how the genetic findings are
linked to treatment response to triptans (which constrict
the blood vessels of the brain), nor to responses to calci-
tonin gene-related peptide (CGRP) antagonists and CGRP-
blocking antibodies (CGRP levels have been found to be
raised during migraine attacks in some individuals) [9].
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going discussion concerning site of action of these drugs
because, although the triptans have both vascular and
neuronal effects, the new CGRP antibodies have a molecu-
lar size too large to get across the blood brain barrier. The
genetic findings therefore provide insight for new study de-
signs, suggesting a revised approach and a focus on vascu-
lar influences, that may address questions of individualized
treatment responses and potential new treatment options.
Moving towards more personalized care is certainly the
goal, but getting there will need well-designed studies with
larger sample sizes and a deeper understanding of how low
frequency and rare variants influence the disease traits.Authors’ contributions
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